Multiple Myeloma Roundtable: Immunotherapies & MRD Debate
Each year during the ASH Annual Meeting & Exposition, Patient Power brings together several of the world’s leading experts in multiple myeloma for a roundtable discussion of the latest myeloma research and news. Hear from three renowned experts and Patient Power co-founder Andrew Schorr as they discuss the state of multiple myeloma treatment today including advances in immunotherapy, new promising drug options, the role of minimal residual disease (MRD) testing in determining treatment paths, and other important topics including disparities in multiple myeloma care.
1 in 3 patients reports gaps in knowledge of cancer treatment adverse effects
When meeting with an oncologist to discuss treatment plans, newly diagnosed patients with cancer must process significant amounts of new information.
New Cancer Treatments – Immunotherapy and Targeted Therapy
You might have heard about immunotherapy and targeted therapy in the news or your doctors may have recommended them as part of your treatment. But what exactly are they? And how are they different from traditional chemotherapy?
Immunotherapy for Blood Cancer
With so many treatments for blood cancer, one option is immunotherapy. Here's what you should know.
CAR T-cell therapy: Reprogramming the immune system to treat cancer | Rob Weinko...
At the Malaghan Institute for Biomedical Reserach,researchers are developing third generation CAR-T immunotherapy treatments which aim to be more effective with less side effects than previous therapies.